Log in

NASDAQ:CDXC - Chromadex Stock Price, Forecast & News

$4.36
-0.10 (-2.24 %)
(As of 01/19/2020 01:02 AM ET)
Add
Compare
Today's Range
$4.35
Now: $4.36▼
$4.55
50-Day Range
$3.53
MA: $4.24▼
$4.75
52-Week Range
$2.68
Now: $4.36▼
$4.95
Volume154,527 shs
Average Volume208,821 shs
Market Capitalization$259.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.4
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CDXC
Previous Symbol
CUSIPN/A
CIK1386570
Webhttp://www.chromadex.com/
Phone310-388-6706

Debt

Debt-to-Equity Ratio0.04
Current Ratio3.30
Quick Ratio2.41

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$31.56 million
Price / Sales8.23
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.49 per share
Price / Book8.90

Profitability

EPS (Most Recent Fiscal Year)($0.61)
Net Income$-33,320,000.00
Net Margins-74.55%
Return on Equity-137.97%
Return on Assets-72.62%

Miscellaneous

Employees100
Outstanding Shares59,580,000
Market Cap$259.77 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:CDXC Rates by TradingView

(Ad)


The audience GASPED when he revealed how you could collect 100% on your savings every year... for life.

Chromadex (NASDAQ:CDXC) Frequently Asked Questions

What is Chromadex's stock symbol?

Chromadex trades on the NASDAQ under the ticker symbol "CDXC."

How were Chromadex's earnings last quarter?

Chromadex Corp (NASDAQ:CDXC) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). The business had revenue of $12.05 million for the quarter, compared to the consensus estimate of $11.66 million. Chromadex had a negative return on equity of 137.97% and a negative net margin of 74.55%. View Chromadex's Earnings History.

When is Chromadex's next earnings date?

Chromadex is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Chromadex.

What price target have analysts set for CDXC?

3 analysts have issued 1 year price objectives for Chromadex's stock. Their forecasts range from $6.00 to $7.00. On average, they expect Chromadex's stock price to reach $6.67 in the next year. This suggests a possible upside of 52.9% from the stock's current price. View Analyst Price Targets for Chromadex.

What is the consensus analysts' recommendation for Chromadex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chromadex.

What are Wall Street analysts saying about Chromadex stock?

Here are some recent quotes from research analysts about Chromadex stock:
  • 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (1/15/2020)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We apply a 26.6x EV-to-EBITDA multiple applied to our 2020 EBITDA per share estimate of $0.35, discounted back at a 12% rate, which yields a price objective of approximately $7.00 per share." (4/25/2019)

Has Chromadex been receiving favorable news coverage?

News stories about CDXC stock have been trending somewhat negative on Sunday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chromadex earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Chromadex.

Who are some of Chromadex's key competitors?

What other stocks do shareholders of Chromadex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include Tilray (TLRY), Heron Therapeutics (HRTX), TransEnterix (TRXC), Athersys (ATHX), Glu Mobile (GLUU), Axsome Therapeutics (AXSM), CELYAD SA/ADR (CYAD), Mesoblast (MESO), Sorrento Therapeutics (SRNE) and Nabriva Therapeutics (NBRV).

Who are Chromadex's key executives?

Chromadex's management team includes the folowing people:
  • Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)
  • Mr. Robert N. Fried, CEO & Director (Age 59)
  • Mr. Kevin M. Farr, Chief Financial Officer (Age 61)
  • Mr. Ben Shichman, Chief Technology Officer
  • Dr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation

How do I buy shares of Chromadex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Chromadex's stock price today?

One share of CDXC stock can currently be purchased for approximately $4.36.

How big of a company is Chromadex?

Chromadex has a market capitalization of $259.77 million and generates $31.56 million in revenue each year. The company earns $-33,320,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Chromadex employs 100 workers across the globe.View Additional Information About Chromadex.

What is Chromadex's official website?

The official website for Chromadex is http://www.chromadex.com/.

How can I contact Chromadex?

Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected]


MarketBeat Community Rating for Chromadex (NASDAQ CDXC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  452 (Vote Outperform)
Underperform Votes:  509 (Vote Underperform)
Total Votes:  961
MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Featured Article: Why do earnings reports matter?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel